Short answer
Sionna Therapeutics, Inc. (SION) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$32M
- −59.9% YoY · −8.5% QoQ
- EPS (diluted)
- −$0.73
- −100.1% YoY · −12.3% QoQ
Source: XBRL data from the Sionna Therapeutics, Inc. (SION) Q3 2026 10-Q on SEC EDGAR. USD.
Sionna Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales
- Net loss $32.4M vs $20.3M YoY, operating margin not applicable
- NBD1 and combination R&D $10.5M vs $8.6M, strongest program spending
- Cash, equivalents and marketable securities $249.8M, runway into second half of 2029
- Operating cash use $62.8M vs $49.7M; workforce reduction approximately 46%, SION-451 plus SION-2222 Phase 2 expected Q1 2027
Risk Factors
- Newly triggered supply-chain risk: BIOSECURE Act exposure after a Chinese manufacturer joined the Section 1260H list on June 8, 2026
- Most updated clinical risk: SION-719 discontinuation after PreciSION CF missed its sweat-chloride endpoint, concentrating prospects on SION-451 + SION-2222
- Regulatory risk: FDA scrutiny of foreign clinical data could require additional trials for U.S. approval
- Near-term operational risk: AscenSION CF requires patients to switch from Trikafta, increasing enrollment and retention challenges
- Financial risk: $249.8 million cash, cash equivalents and marketable securities expected to fund operations into the second half of 2029
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Sionna Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.